About us Contacts Drug interactions: 390 212
Drug search by name

Adalimumab-adbm Subcutaneous and Interferon Alfa-2b Injection Solution

Determining the interaction of Adalimumab-adbm Subcutaneous and Interferon Alfa-2b Injection Solution and the possibility of their joint administration.

Check result:
Adalimumab-adbm Subcutaneous <> Interferon Alfa-2b Injection Solution
Relevance: 19.07.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Using interferon alfa-2b together with adalimumab may increase the risk of nerve damage, which is a potential side effect of both medications. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Let your doctor know if you develop weakness, numbness, pain, burning, or tingling in your hands, feet, or limbs. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR: The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years. In some cases, the neuropathy may progress or become irreversible despite discontinuation of the medications.

MANAGEMENT: Caution is advised during concomitant use of agents with neurotoxic effects. Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage. If feasible, therapy should generally be reinstituted only after resolution of neuropathy symptoms or return of symptoms to baseline status. In some cases, permanent dosage reductions may be required.

References
  • Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201
  • Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6
  • Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):
  • EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."
Adalimumab-adbm Subcutaneous

Generic Name: adalimumab

Brand name: Humira, Humira Pen, Humira Pen Crohns/UlcerColit/HidraSuppur, Humira Pen Psoriasis/Uveitis Starter Package, Humira Pediatric, Humira Pediatric Crohn's Disease Starter Pack, Humira Pre-Filled Syringe, Humira Pen Psoriasis/Uveitis/Adol HidraSuppur Starter Pack, Humira Pen Crohns/Ulcer Colitis/Hidradenitis Suppurati StrPk

Synonyms: Adalimumab

Interferon Alfa-2b Injection Solution

Generic Name: interferon alfa-2b

Brand name: Intron A

Synonyms: Interferon alfa-2b, Interferon Alfa-2b

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.